Endogenous Cushing syndrome
Corcept Therapeutics Inc. is involved in clinical research on endogenous Cushing syndrome, with attention to the long-term management of the signs and symptoms associated with excess cortisol activity.
- Relacorilant
- CORT125134
- Safety and tolerability
The sponsor’s work in this area centers on endocrine disease and the clinical management of chronic hypercortisolism.
Amyotrophic lateral sclerosis
Its research portfolio includes amyotrophic lateral sclerosis, focusing on treatment options for a progressive neurodegenerative disorder affecting motor function.
- Dazucorilant
- Neuromuscular disease
- Safety assessment
Clinical activity in this field reflects interest in neurodegeneration and disorders with unmet therapeutic need.
Gynecological cancers
Corcept Therapeutics Inc. is active in gynecological cancers, including advanced, platinum-resistant ovarian cancer, fallopian-tube cancer, and primary peritoneal cancer.
- Relacorilant in combination therapy
- Progression-free survival
- Solid tumours
The sponsor’s oncology research also spans recurrent and treatment-resistant disease settings within gynecologic oncology.
